To reach these high ambitions, we foster a culture of transparency, based on open exchange across the entire organization. We are solution-oriented in our thinking, and we do more with less while genuinely enjoying our daily experiences.
We provide our employees with exciting opportunities for professional growth. We work collaboratively to progress our drug portfolio and build a commercial infrastructure.
Year of birth: 1968
Nationality: Swiss
Education: Master’s degree in Business Administration, Monetary Economics and Corporate Law from the University of Zurich and Chartered Financial Analyst (CFA).
Professional background: Built a deep expertise and network in the area capital markets, while focusing on gaining an understanding for the pharmaceutical and biotechnology market. Stepping stones as sell-side analyst, buy-side analyst and fund manager include: Equity analyst for European Pharmaceuticals at Warburg Dillon Read (1997–1999) and analyst/ fund manager at Julius Baer (2000–2005). Senior financial analyst covering Swiss/European pharmaceutical/biotechnology stocks for Bank Leu (2005), Bank Sarasin (2006) and Bank Vontobel (2007). Team leader for Life Sciences Equity Research at Bank Vontobel (2008–2014). Head of Investor Relations & Corporate Communications for Actelion 2014-2017. Joined Idorsia as Head of Investor Relations & Corporate Communications when the company was established in June 2017.
Year of birth: 1973
Nationality: French
Education: PhD in Chemistry from the Institute of Organic Chemistry in Basel, Switzerland. MSc in chemistry from the Haute Alsace University, France and a Chemistry Engineering Diploma from the Ecole Nationale Supérieure de Chimie de Mulhouse, France, in 1997.
Professional background: Worked up from laboratory head, 2003, and project leader in Drug Discovery Chemistry in Actelion to group leader leading the chemistry team within the immunology therapeutic area at Idorsia.
Year of birth: 1978
Nationality: Swiss and Russian
Education: Master degree in Human Resources Management in Russia, Bachelor degree in Finance in Russia; further education and training in Business Administration and Communication in the US (California State University East Bay, Hayward) and in Coaching and Neuro-linguistic Programming in Erickson College, Vancouver, Canada.
Professional background: HR Manager and Organizational Development Manager at British American Tobacco in Russia and in Switzerland 2003-2007; HR Director for Global Clinical Development and Head of Global Talent Acquisition and Development at Actelion 2007-2017. As of 2013 practicing independent professional coach. Joined Idorsia as Head of Human Resources when the company was established in June 2017.
Other Group functions: None.
Year of birth: 1972
Nationality: German
Education: Technical Assistant in biological research 1994. MSc in Biology from the University of Osnabrück, Germany 2004. MSc in Applied Toxicology from the University of Surrey, UK 2013.
Professional background: Worked with increased responsibilities from lab technician in toxicology up to scientist in a contract research organization. Joined Actelion Pharmaceuticals in 2005 as Project Toxicologist and after moving to Idorsia became Group leader in Toxicology in 2019.
Year of birth: 1962
Nationality: Swiss
Education: Doctoral degree. Dr. Phil.II at the University of Basel, Switzerland, further education at Stanford University, School of Medicine, Stanford, CA, US.
Professional background: Research Scientist, Thrombosis Group at Hoffmann-La Roche, 1994-1997. Project Leader “Novel Oral Anticoagulant Project” at Hoffmann-La Roche, 1997-2002. Head of Biology, Axovan Pharmaceutical, 2002-2003. Senior Group Leader, Immunology/Thrombosis Biology at Actelion Pharmaceuticals Ltd, 2003-2016. Head DD Biology, at Actelion Pharmaceuticals Ltd, 2016-2017. Joined Idorsia as Head of Drug Discovery Biology when the company was established in June 2017.
Year of birth: 1966
Nationality: French
Education: Ph.D. in applied Physico-Chemistry (polymer sciences) in France.
Professional background: 1998–2005. Principal Scientist and Technology Matrix Leader for Parenteral Sustained Delivery systems in the Pharmaceutical Department of Novartis Pharma AG, 2005-2013 CMC project leader at Actelion Pharmaceuticals Ltd, 2013 - 2017 Head Quality Assurance (GMP/GDP) at Actelion Pharmaceuticals Ltd. Joined Idorsia as Head of Pharmaceutical Development when the company was established in June 2017.
The Board of the company currently consists of six non-executive members, five of whom are considered by the Board to be independent in character and judgment. The Board performs regular reviews of its composition as to background, function and experience, in order to ensure diversity and to balance valuable experience of Idorsia’s business with fresh perspectives.
Under Articles 13 and 16 of the Articles of Association, the 3–9 members of the Board of Directors are elected individually by the General Meeting of the Shareholders for a term of office corresponding to the legally permitted maximum term of one year. One year of office is understood to be the period from one ordinary Meeting of the Shareholders to the next ordinary Meeting of the Shareholders.
| Executive Member |
Date of AGM of first election |
Date of AGM of end of term |
|
| Jean-Paul Clozel | No | 2017 | 2025 |
| Mathieu Simon | No | 2019 | 2025 |
| Bart Filius | No | 2024 | 2025 |
| Srishti Gupta | No | 2021 | 2025 |
| Sophie Kornowski | No | 2023 | 2025 |
| Sandy Mahatme | No | 2021 | 2025 |
